CEO Sells $7.5 Million in Stock After Option Exercise
PTGX has more than doubled off its 52-week low of $43.2.
Summary
Protagonist Therapeutics' CEO sold $7.5 million in company stock after exercising options, contributing to a recent trend of insider sales despite strong Q1 earnings.
Key Events · Ownership and Investor Activity · PTGX
-
CEO Stock Sale
CEO Dinesh V. Patel sold 75,000 shares of common stock for $7,509,000 at an average price of $100.12 per share.
-
Option Exercise
The sale followed the exercise of options for 75,000 shares at a strike price of $21.58, valued at $1,618,500.
-
Insider Selling Trend
This transaction adds to a pattern of insider sales totaling nearly $20 million over the last 90 days, including recent sales by the CFO and a Director.
-
Post-Earnings Sale
The sale occurred shortly after the company reported a profitable Q1 2026, marking a significant financial turnaround.
Analysis · PTGX · Life Sciences
Protagonist Therapeutics' CEO, Dinesh V. Patel, sold $7.5 million worth of common stock after exercising options. This transaction follows recent positive Q1 earnings, and contributes to a broader pattern of insider sales observed over the past 90 days. While exercising options and selling is a common practice for executives to realize gains, the magnitude of the sale by the CEO could be interpreted as profit-taking rather than a strong signal of future growth confidence, especially given the recent financial turnaround.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PTGX was trading at $99.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.4B. The 52-week trading range was $43.20 to $107.84. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.